We can’t show the full text here under this license. Use the link below to read it at the source.
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE C anada multicentre, prospective, observational study
Once-weekly semaglutide use in people with type 2 diabetes during regular medical care: Results from a Canadian multi-center study
AI simplified
Abstract
In total, 452 patients initiated semaglutide, with a mean baseline HbA1c of 8.1%.
- Mean HbA1c was reduced by 0.9%-point at the end of the study.
- Mean body weight decreased by 4.3 kg by the end of the study.
- At the end of the study, 46.9% of patients achieved an HbA1c of less than 7.0%.
- 40.9% of patients achieved a weight loss of 5% or higher.
- 24.1% of patients met the composite endpoint of HbA1c reduction of 1% or more and weight loss of 3% or more.
- Patient-reported outcomes improved from baseline to the end of the study, with no new safety concerns reported.
AI simplified
Key numbers
0.9%-point
HbA1c Reduction
Mean change from baseline HbA1c of 8.1%
4.3 kg
Weight Loss
Mean change in body weight
46.9%
Achieved HbA1c Target
Patients achieving HbA1c <7% at end of study